
Malin Holm Meyer-Myklestad
- Senior physician, research scientist; MD, PhD
- +47 22 11 88 51
Publications 2023
A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation
Hepatology, 77 (3), 715-728
DOI 10.1002/hep.32773, PubMed 36056902
Reply: The mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. Is the dysbiosis index really predictive for the recurrence of PSC?
Hepatology, 77 (6), E188-E189
DOI 10.1097/HEP.0000000000000340, PubMed 36815351
Publications 2022
Human Immunodeficiency Virus-Infected Immunological Nonresponders Have Colon-Restricted Gut Mucosal Immune Dysfunction
J Infect Dis, 225 (4), 661-674
DOI 10.1093/infdis/jiaa714, PubMed 33216130
Probiotics to HIV-Infected Immunological Nonresponders: Altered Mucosal Immunity and Microbial Diversity Restricted to Ileum
J Acquir Immune Defic Syndr, 89 (1), 77-86
DOI 10.1097/QAI.0000000000002817, PubMed 34878437
Publications 2021
Enhanced Gut-Homing Dynamics and Pronounced Exhaustion of Mucosal and Blood CD4+ T Cells in HIV-Infected Immunological Non-Responders
Front Immunol, 12, 744155
DOI 10.3389/fimmu.2021.744155, PubMed 34691047
Publications 2020
Probiotics to manage inflammation in HIV infection
Curr Opin Infect Dis, 33 (1), 34-43
DOI 10.1097/QCO.0000000000000612, PubMed 31789692
Publications 2011
An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses
J Virol, 85 (13), 6557-66
DOI 10.1128/JVI.00073-11, PubMed 21490090
Publications 2010
[Buy a uniform--support a nurse!]
Tidsskr Nor Laegeforen, 130 (17), 1738-9
DOI 10.4045/tidsskr.10.0748, PubMed 20835288
Publications 2008
PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples
Curr HIV Res, 6 (1), 49-58
DOI 10.2174/157016208783571955, PubMed 18288975
Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment
J Infect Dis, 198 (10), 1474-81
DOI 10.1086/592713, PubMed 18851688